Rheumatology is the branch of medicine that deals with rheumatic diseases.

What are rheumatic diseases?

Rheumatic diseases affect the joints, connective tissues and muscles. There are over 100 different rheumatic diseases, with symptoms that range from inflammation to loss of function of the affected body part. Well-known rheumatic diseases include osteoarthritis, rheumatoid arthritis, gout, infectious arthritis, juvenile idiopathic arthritis, fibromyalgia and scleroderma.

Which medicines do we provide for rheumatic diseases?

Browse medicines that have been approved for specific rheumatic diseases by clicking on a specific disease. If a medicine has been approved by at least one reputable medical authority in the world and is not available in your country, you may be able to purchase it via our service; we may be able to source and deliver it to you if you can provide a prescription from your doctor. 

  1. Kevzara (sarilumab)
    Kevzara (sarilumab)
    by Sanofi - Aventis Groupe
    for Rheumatoid Arthritis
  2. Olumiant (baricitinib)
    Olumiant (baricitinib)
    by Eli Lilly Nederland B.V.
    for Rheumatoid Arthritis
  3. Taltz (ixekizumab)
    Taltz (ixekizumab)
    by Eli Lilly Nederland B.V.
    for Psoriasis
  4. Tymlos (abaloparatide)
    Tymlos (abaloparatide)
    by Radius Health, Inc.
    for Osteoporosis
  5. Xeljanz (tofacitinib)
    Xeljanz (tofacitinib)
    by Pfizer Limited
View as Grid List

5 Items

per page
Set Descending Direction

One more step before you can continue

Our service contains information about acquiring medicines that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

Scroll down.

No, I'd like to receive general information only.

Disclaimer: The information TSM provides is aimed at patients with terminal and life-debilitating diseases, their doctors and healthcare professionals. It supports an informed decision by the treating doctor about the patient’s treatment and the consideration of a medicine which has not been approved in the patient’s country.